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ABSTRACT 
Approximately 90% of melanomas arise from skin sites (known as cutaneous malignant 
melanoma; CMM), whereas the non-cutaneous melanoma (mucosal and ocular melanomas) 
are rare, accounting for about 10%. Familial melanoma accounts for up to 10% of patients 
diagnosed with CMM. Both genetics (e.g. CDKN2A and CDK4 germline mutations, as well as 
polymorphisms in MC1R and other genes) and environmental factors (ultraviolet radiation) 
contribute to the induction of melanoma. The MAPK and the PI3K are the two most 
commonly activated signaling cascades in melanomas. Activation of these two pathways 
occurs frequently through alterations in BRAF, NRAS and KIT oncogenes. The involvement of 
these oncogenes in common CMM subtypes is well-studied. However, the frequency of 
mutations in BRAF, NRAS and KIT and also PTEN has not been well-characterized in the other 
rare melanoma subtypes, at least not in Caucasian populations. The overall aim of this thesis 
was to better define the molecular genetic alterations of BRAF, NRAS and KIT in different 
subtypes of melanomas and to correlate the mutation status with the histopathological features 
of the tumors and with the clinical parameters of the patients. 
 
For the first project, Formalin-fixed paraffin embedded samples of primary familial and 
sporadic CMMs were collected from eight centers in Europe and Australia. The overall aim 
was to better define the frequencies of BRAF and NRAS mutations in familial melanoma with 
and without germline CDKN2A mutations. Overall, 89 tumors from patients with germline 
CDKN2A mutations, 46 from patients without germline CDKN2A mutations, and 50 sporadic 
melanomas were analyzed for BRAF exon 15 and NRAS (exon 2) mutations using direct DNA 
sequencing. The tumors were also evaluated for pERK and pAkt expression by 
immunohistochemistry (IHC). The BRAF and NRAS mutation frequencies detected in familial 
melanomas were 43% and 11%, respectively. These frequencies did not differ significantly 
between tumors from germline CDKN2A mutation carriers and non-carriers. The frequency of 
BRAF mutation (41%) and NRAS mutation (12%) in the sporadic melanomas did not differ 
significantly from that identified in the familial melanomas. Expression of pERK and pAkt 
was observed in 65% and 46% of the familial melanomas, respectively. Similar frequencies of 
pERK and pAkt expressions were observed in the sporadic melanomas. 
 
In the second project, we analyzed a large number of a rare subtype of melanoma; sinonasal 
mucosal melanoma. In total, 56 primary tumors were screened for mutations in KIT (exons 11, 
13 and 17), NRAS (exons 1 and 2) and BRAF exon 15 using direct sequencing. Twelve of the 
56 (21%) tumors contained one mutation in these oncogenes; 2 tumors harbored KIT 
mutations, another 2 harbored BRAF mutations and 8 had NRAS mutations. The mutations 
were more frequently detected in tumors originated from the paranasal sinuses than from the 
nasal cavity (p=0.045). Patients with melanoma in the paranasal sinuses had a worse overall 
survival than patients with melanoma in the nasal cavity(p=0.027). 
 
In the third project, primary and metastatic acral lentiginous melanomas were investigated for 
mutations in BRAF (exons 11 and 15), NRAS (exons 1 and 2), KIT (exons 9, 11, 13, 17 and 18) 
and PTEN (exons 1, 3-6 and 10-12) by direct sequencing. The data showed an identical 
mutation frequency of 15% (13 out of 88) of both KIT and NRAS, whereas BRAF mutations 
were found in 17% (15 out of 88) of the primary tumors. Of the 25 cases evaluated for PTEN 
mutations, only one tumor contained a mutation (4%). The BRAF, NRAS and KIT mutation 
status in 16 metastases was similar to that identified in the matched primaries. In comparison 
with BRAF wild-type tumors, BRAF mutated tumors were more commonly diagnosed in 
young individuals (p=0.028) and significantly associated with tumor location on the feet 
(p=0.039) and female gender (p=0.039). The anatomical site was an independent prognostic 
factor with better overall survival for patients with tumors on hand or subungual areas than 
those with tumors on the feet or under toenails (p=0.025). 
 
In the fourth project, we evaluated 124 primary and 76 metastatic (including 73 matched 
metastases) CMMs for BRAFV600E expression by IHC using VE1 antibody. Overall, 55% (110 
out of 200) tumors displayed a positive homogenous staining. There was a consistency in 
BRAFV600E staining between the matched primaries and metastatic CMMs. In 28 tumors a 
discrepancy was observed between the VE1 staining and the mutation analysis methods. Re-
analysis of 25 tumors of the discrepant cases by pyrosequencing revealed a new BRAFV600E 
mutation in three cases, supporting the results seen with VE1 staining. In the remaining 22 
tumors the results of the pyrosequencing and the initial mutation methods were similar. 
Overall sensitivity and specificity with VE1 antibody staining were 97% and 80%, 
respectively. 
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